The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers.
The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers.
复制标题
DOI：
10.3390/cancers10100356
复制
发表时间：
2018-09-26
期刊：
影响因子：
5.2
通讯作者：
Kasuya H
中科院分区：
文献类型：
--
作者：
Eissa IR;Bustos-Villalobos I;Ichinose T;Matsumura S;Naoe Y;Miyajima N;Morimoto D;Mukoyama N;Zhiwen W;Tanaka M;Hasegawa H;Sumigama S;Aleksic B;Kodera Y;Kasuya H
自2015年美国食品药品监督管理局（FDA）和欧洲药品管理局（EMA）批准拉他莫基（talimogene laherparepvec）（T-VEC，Imlygic®）用于黑色素瘤治疗以来，溶瘤病毒疗法已被接受为标准免疫疗法。各种溶瘤病毒（OV），如HF 10（Canerpaturev-C-REV）和CVA 21（CAVATAK），目前正在积极开发II期单药治疗，或与免疫检查点抑制剂联合治疗黑色素瘤。此外，在神经胶质瘤中，几种OVs在I期临床试验中已清楚地证明了安全性和有希望的疗效。此外，几种OV的安全性，如pelareorep（Reolysin®），证明了它们与紫杉醇组合在乳腺癌患者中的安全性和有效性，但OV作为针对乳腺癌的单一疗法的结果尚未为OV提供明确的治疗策略。OV抗胰腺癌的临床试验尚未证明作为单药治疗或作为联合治疗的一部分的疗效。然而，有几种溶瘤病毒已经在不同的临床前模型中成功证明了它们的功效。在这篇综述中，我们主要集中在溶瘤病毒，过渡到临床试验对黑色素瘤，神经胶质瘤，胰腺癌和乳腺癌。因此，我们描述了OV对黑色素瘤、神经胶质瘤、胰腺癌和乳腺癌的临床试验的现状和未来前景。
Oncolytic viral therapy has been accepted as a standard immunotherapy since talimogene laherparepvec (T-VEC, Imlygic®) was approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) for melanoma treatment in 2015. Various oncolytic viruses (OVs), such as HF10 (Canerpaturev—C-REV) and CVA21 (CAVATAK), are now actively being developed in phase II as monotherapies, or in combination with immune checkpoint inhibitors against melanoma. Moreover, in glioma, several OVs have clearly demonstrated both safety and a promising efficacy in the phase I clinical trials. Additionally, the safety of several OVs, such as pelareorep (Reolysin®), proved their safety and efficacy in combination with paclitaxel in breast cancer patients, but the outcomes of OVs as monotherapy against breast cancer have not provided a clear therapeutic strategy for OVs. The clinical trials of OVs against pancreatic cancer have not yet demonstrated efficacy as either monotherapy or as part of combination therapy. However, there are several oncolytic viruses that have successfully proved their efficacy in different preclinical models. In this review, we mainly focused on the oncolytic viruses that transitioned into clinical trials against melanoma, glioma, pancreatic, and breast cancers. Hence, we described the current status and future prospects of OVs clinical trials against melanoma, glioma, pancreatic, and breast cancers.
登录
查看更多内容
影响因子：
4.7
作者：
Eissa IR;Naoe Y;Bustos-Villalobos I;Ichinose T;Tanaka M;Zhiwen W;Mukoyama N;Morimoto T;Miyajima N;Hitoki H;Sumigama S;Aleksic B;Kodera Y;Kasuya H
通讯作者：
Kasuya H
DOI：
10.1016/j.ymthe.2017.08.016
发表时间：
2017-12-06
期刊：
Molecular therapy : the journal of the American Society of Gene Therapy
影响因子：
--
作者：
Geletneky K;Hajda J;Angelova AL;Leuchs B;Capper D;Bartsch AJ;Neumann JO;Schöning T;Hüsing J;Beelte B;Kiprianova I;Roscher M;Bhat R;von Deimling A;Brück W;Just A;Frehtman V;Löbhard S;Terletskaia-Ladwig E;Fry J;Jochims K;Daniel V;Krebs O;Dahm M;Huber B;Unterberg A;Rommelaere J
通讯作者：
Rommelaere J
影响因子：
3.8
作者：
Bernstein, V.;Ellard, S. L.;Seymour, L.
通讯作者：
Seymour, L.
影响因子：
12.4
作者：
Galanis, Evanthia;Markovic, Svetomir N.;Kendra, Kari
通讯作者：
Kendra, Kari
影响因子：
45.3
作者：
Chesney, Jason;Puzanov, Igor;Kaufman, Howard L.
通讯作者：
Kaufman, Howard L.